Cancer Biology Research

To provide fundamental information on the cause and nature of cancer in people, with the expectation that this will result in better methods of prevention, detection and diagnosis, and treatment of neoplastic diseases.

Cancer Biology Research includes the following research programs: cancer cell

credit:
biology, cancer etiology, structural biology and molecular applications, DNA and chromosomal aberrations, tumor biology and metastasis, and immunology andhematology.

Small Business Innovation Research (SBIR) program: To expand and improve the SBIR program; to increase private sector commercialization of innovations derived from Federal participation in Federal research and development; and to foster and encourage participation of socially and economically disadvantaged small business concerns and women-owned small business concerns in technological innovation.

Small Business Technology Transfer (STTR) program: To stimulate and foster scientific and technological innovation through cooperative research and development carried out between small business concerns and research institutions; to foster technology transfer; increase private sector commercialization of innovations derived from Federal research and development; and to foster and encourage participation of socially and economically disadvantaged small business concerns and women-owned small business concerns in technological innovation.
Related Programs

Examples of Funded Projects

(1) Studies of the properties of the membranes of malignant cells; (2) studies of the molecular genetics of oncogenes and tumor suppressor genes and the proteins they encode; (3) studies of the mechanism of action of growth factors and other growth modifiers and differentiation agents; (4) studies of the regulation of the biology of tumor cells by their micro environment; (5) studies of the synthesis, structure, and function of humoral factors that participate in, activate, and/or regulate the immune response to tumors, including interferons, interleukins, growth factors, helper factors, suppressor factors, etc., as they are involved in immune responses to tumors; (6) studies of the immunobiology of lymphocytes, macrophages, and other cells that may participate in immune surveillance responses (e.g., natural killer cells and cytotoxic T cells); (7) studies of the immune mechanisms involved in effective immunotherapy in animal models and humans, including studies on the development vaccine approaches to cancer therapy or prevention; (8) studies of bone marrow transplantation in humans and animals as a treatment for cancer when the emphasis is on immunologic problems such as immune reconstitution, sensitization and graft-versus-host disease.


Agency - Department of Health and Human Services

The Department of Health and Human Services is the Federal government's principal agency for protecting the health of all Americans and providing essential human services, especially to those who are least able to help themselves.

Website Address

http://www.nih.gov


Relevant Nonprofit Program Categories





Selected Recipients for this Program


RecipientAmount Start DateEnd Date
Cleveland Clinic Lerner College Of Medicine/cwru $ 420,976   2014-08-152019-07-31
Dana-farber Cancer Institute, Inc. $ 2,533,281   1989-07-012019-07-31
Trustees Of Princeton University, The $ 2,427,500   2013-09-302018-08-31
Trustees Of Boston University $ 710,161   2010-06-082016-05-31
Hemosonics, Llc $ 202,931   2014-07-092016-03-31
Novab, Inc. $ 149,036   2014-09-252016-03-24
University Of California, Davis $ 1,673,148   2010-04-012016-01-31
Trustees Of The University Of Pennsylvania, The $ 1,573,613   2010-04-012016-01-31
Virginia Commonwealth University $ 1,599,061   2010-04-012016-01-31
University Of Texas Health Science Center Of San Antonio $ 1,476,814   2010-03-012015-12-31



Program Accomplishments

Competing FY 07 RPG act. 306 awards, which were 17.7 percent of applications received. Competing FY 07 SBIR/STTR act. 18 awards, which were 23.1 percent of applications received. Fiscal year 08 est 1,509 total awards and FY 09 est 1,489 total awards.

Uses and Use Restrictions

Grants and cooperative agreements may be made to eligible institutions for the support of cancer research projects.

The grants and cooperative agreements may be used for personnel, consultant costs, equipment, supplies, travel, patient costs, animals, alterations and renovations, miscellaneous items, and Facilities and Administrative Costs (formerly known as indirect costs).

SBIR Phase I grants (of approximately 6-months' duration) are to establish the technical merit and feasibility of a proposed research effort that may lead to a commercial product or process.

Phase II grants are for the continuation of the research initiated in Phase I and that are likely to result in commercial products or processes.

Only Phase I awardees are eligible to receive Phase II support.

STTR Phase I grants (normally of 1-year duration) are to determine the scientific, technical and commercial merit and feasibility of the proposed cooperative effort that has potential for commercial application.

Phase II are for the continuation of the research initiated in Phase I that is likely to result in a commercial product.

The SBIR/STTR Fast Track Initiative provides additional assistance to applicants by expediting the decision and award of SBIR Phase II funding for scientifically meritorious applications for projects that have a high potential for commercialization.

Fast-Track is a parallel review option whereby Phase I and Phase II projects are reviewed concurrently with the aim of reducing or eliminating the funding gap between Phase I and Phase II.

Eligibility Requirements

Applicant Eligibility

The awardee will be a university, college, hospital, public agency, nonprofit research institution or for-profit organization that submits an application and receives a grant for support of research by a named principal investigator.

SBIR grants can be awarded only to domestic small businesses (entities that are independently owned and operated for profit, are not dominant in the field in which research is proposed and have no more than 500 employees).

Primary employment (more than one-half time) of the principal investigator must be with the small business at the time of award and during the conduct of the proposed project.

In both Phase I and Phase II, the research must be performed in the U.S.

and its possessions.

To be eligible for funding, a grant application must be approved for scientific merit and program relevance by a scientific review group and a national advisory council.

STTR grants can be awarded only to domestic small business concerns (entities that are independently owned and operated for profit, are not dominant in the field in which research is proposed and have no more than 500 employees)which "partner" with a research institution in cooperative research and development.

At least 40 percent of the project must be performed by the small business concern and at least 30 percent by the research institution.

In both Phase I and Phase II, the research must be performed in U.S.

and its possessions.

To be eligible for funding, a grant application must be approved for scientific merit and program relevance by a scientific review group and a national advisory council.

Beneficiary Eligibility

Any nonprofit or for-profit organization, company, or institution engaged in biomedical research.

Credentials/Documentation

Costs will be determined in accordance with OMB Circular No. A-87 for State and local governments. For-profit organizations' costs are determined in accordance with Subpart 31.2 of the Federal Acquisition Regulations. For other grantees, costs will be determined in accordance with HHS Regulations 45 CFR Part 74, Subpart Q. For SBIR and STTR grants, applicant organization (small business concern) must present in a research plan an idea that has potential for commercialization and furnish evidence that scientific competence, experimental methods, facilities, equipment, and funds requested are appropriate to carry out the plan. Grant form SF424(R&R) is used to apply for SBIR Phase I and Phase II, STTR Phase I and Phase II grants, and Fast-Track.

Aplication and Award Process

Preapplication Coordination

None.

This program is excluded from coverage under E.O.

12372.

Application Procedures

The NIH is in the process of a transition to fully electronic grant submission through Grants.gov (see http://era.nih.gov/ElectronicReceipt for details). Depending on the grant mechanism, either form PHS-398 (Rev. September 2004) or form SF424(R&R) (October 2005) is the standard form. Both can be obtained at http://grants1.nih.gov/grants/forms.htm. The standard application forms, as furnished by PHS and required by 45 CFR, Part 92 for State and local governments, must be used for this program. This program is subject to the provisions of 45 CFR, Part 92 for State and local governments and OMB Circular No. A-110 for nonprofit organizations, as appropriate. SBIR and STTR Grant Solicitations and SBIR Contract Solicitation may be obtained electronically through the NIH's "Small Business Funding Opportunities" home page at www.nih.gov/grants/funding/sbir.htm on the World Wide Web. The Solicitations include submission procedures, review considerations, and grant application or contract proposal forms. All competing SBIR and STTR grant applications must be submitted electronically via Grants.gov The following is a website address for NIH electronic submission of grant application information: http://era.nih.gov/ElectronicReceipt/index.htm.

Award Procedures

Grants and cooperative agreements are funded based on scientific merit, program relevance, and program balance and are made annually. The initial grant award provides funds for the first budget period (usually 12 months) and letter Notice of Award indicates support recommended for the remainder of the project period, allocation of Federal funds by budget categories and special conditions, if any. All accepted SBIR/STTR applications are evaluated for technical merit by an appropriate scientific review group and if they are recommended for further consideration, by a national advisory council. All applications receiving a priority score compete for available SBIR/STTR set-aside funds on the basis of scientific and technical merit and commercial potential of the proposed research, program relevance, and program balance among the areas of research.

Deadlines

All Grants including renewals and supplements: April 5, August 5, December 5. Cooperative Agreements and contracts are usually submitted in response to a Request for Applications (RFA) or a Request for Proposals (RFP). The receipt date is stipulated in the RFA or RFP.

Authorization

Public Health Service Act, Section 301, 410, and 411, Public Law 78-410, 42 U.S.C. 241, as amended; Public Law 100-607, 42 U.S.C. 285 and 285a; Small Business Research and Development Enhancement, Act of 1992, as amended, Public Law 102-564.

Range of Approval/Disapproval Time

Regular Grants: Approximately 10 months. SBIR/STTR: Approximately 7-1/2 months.

Appeals

A principal investigator may question the substantive or procedural aspects of the review of his/her application by communicating with the staff of the Institute. A description of the NIH Peer Review Appeal procedures is available on the NIH home page www.nih.gov/grants/guide/1997/97.11.21/n2.html.

Renewals

Applications submitted for renewal are reviewed and selected for funding on a competitive basis.

Assistance Considerations

Formula and Matching Requirements

None.

Length and Time Phasing of Assistance

Grants and Cooperative Agreements: Average 3 to 4 years, and a maximum of 5 years. Renewals may be awarded for additional periods of up to 5 years based on competitive peer review. Funding is provided through Monthly Demand Payment System or an Electronic Transfer System. SBIR: Normally, Phase I awards are for 6 months; normally, Phase II awards are for 2 years. STTR: Normally, Phase I awards are for 1 year; normally, Phase II awards are for 2 years.

Post Assistance Requirements

Reports

Progress repor